Effects of cholecystokinin peptides and GV 150013, a selective cholecystokinin(B) receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices

Journal of Neurochemistry

Volumn 73, Issue 5, 1999, Pages 1973-1981

  Ferraro, L ^a   Beani, L ^a   Trist, D ^b   Reggiani, A ^b   Bianchi, C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b GSK   (Italy)

Author keywords

Cholecystokinin; Chronic treatment; Electrical stimulation; Slices

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; GV 150013; TETRAGASTRIN; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSTIMULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0032692623     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.01973.x     Document Type: Article

References (45)

1. Abelson J. and Nesse R. (1990) Cholecystokinin-4 and panic. Arch. Gen. Psychiatry 47, 395-399.
2. Baber N. S., Dourish C. T., and Hill D. R. (1989) The role of CCK caerulein, and CCK antagonists in nociception. Pain 39, 307-328.
3. Bartfai T., Iverfeldt K., Fisone G., and Serfozo P. (1988) Regulation of the release of coexisting neurotransmitters. Annu. Rev. Pharmacol. Toxicol. 28, 285-310.
4. Biró E., Penke B., and Telegdy G. (1997) Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rat. Neuropeptides 31, 281-285.
5. Bohme G. A. and Blanchard J. C. (1992) Cholecystokinins and their receptors. Functional aspects. Therapie 47, 541-548.
6. Bourin M., Malinge M., Vasar E., and Bradwejn J. (1996) Two faces of cholecystokinin: anxiety and schizophrenia. Fundam. Clin. Pharmacol. 10, 116-126.
7. Bradwejn J., Koszycki D., and Meterissian G. (1990) Cholecystokinin-tetrapeptide induced panic attacks in patients with panic disorders. Can. J. Psychiatry 35, 83-85.
8. B receptor antagonist. Br. J. Pharmacol. 114, 91P.
9. Costa E, Guidotti A., and Mao C. (1975) Evidence for the involvement of GABA in the actions of benzodiazepines: studies on rat cerebellum, in Mechanism of Actions of Benzodiazepines (Costa E. and Greengard P., eds), pp. 113-154. Raven Press, New York.
10. Crawley J. N. (1988) Neuronal cholecystokinin. ISI Atlas Pharmacol. 2, 84-90.
11. Crawley J. N. (1991) Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12, 232-236.
12. Crawley J. N. and Corwin R. L. (1994) Biological actions of cholecystokinin. Peptides 15, 731-755.
13. Dockray G. J. (1980) Cholecystokinins in rat cerebral cortex: identification, purification and characterization by immunochemical methods. Brain Res. 188, 155-165.
14. Fekete M., Penke B., and Telegdy G. (1982) Effects of cholecystokinin-related peptides on retention of passive avoidance behaviour. Acta Physiol. Acad. Sci. Hung. 60, 237-242.
15. Ferraro L., Tanganelli S., Calò G., Antonelli T., Fabrizi A., Acciarri N., Bianchi C., Beani L., and Simonato M. (1993) Noradrenergic modulation of gamma-aminobutyric acid outflow from the human cerebral cortex. Brain Res. 629, 103-108.
16. Ferraro L., Beani L., Bianchi C., and Tanganelli S. (1997) Inhibitory cholinergic control of endogenous GABA release from electrically stimulated cortical slices and K(+)-depolarized synaptosomes. Neurochem. Int. 31, 795-800.
17. Godukhin O., You Z. B., Herrera-Marschitz M., Goiny M., Pettersson E., Hökfelt T., and Ungerstedt U. (1995) Effect of local cholecystokinin-8 administration on extracellular levels of amino acids and glycolytic products monitored by in vivo microdialysis in the fronto-parietal cortex of the rat. Neurosci. Lett. 194, 29-32.
18. Harro J., Vasar E., and Bradwejn J. (1993) CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14, 244-249.
19. Hendry S. H., Jones E. G., DeFelipe J., Schmechel D., Brandon C., and Emson P. C. (1984) Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc. Natl. Acad. Sci. USA 81, 6526-6530.
20. 3H]GABA from rat cortical slices and cultured mouse cortical neurones. Neurochem. Int. 30, 171-179.
21. Hökfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M., and Markey K. (1980) Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 285, 476-478.
22. Hökfelt T., Cortes R., Schalling M., Ceccatelli S., Pelto-Huikko M., Persson H., and Villar M. J. (1991) Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues. Neuropeptides 19, 31-43.
23. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., and Woodruff G. N. (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 87, 6728-6732.
24. Innis R. B. and Snyder S. H. (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA 77, 6917-6921.
25. Kadar T., Fekete M., and Telegdy G. (1981) Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin octapeptide sulfate ester and nonsulfated cholecystokinin octapeptide. Acta Physiol. Acad. Sci. Hung. 58, 269-274.
26. Kenakin T. (1993) Allotopic, noncompetitive and irreversible antagonism, in Pharmacologic Analysis of Drug-Receptor Interaction, 2nd edit. (Kenakin T., ed), pp. 322-343. Raven Press, New York.
27. McLean H. A., Champagnat J., and Denavit-Saubie M. (1996) A cholecystokinin-B receptor antagonist potentiates GABAergic and glycinergic inhibition in the nucleus of the solitary tract of the rat. Eur. J. Neurosci. 8, 1078-1084.
28. Millhorn D. E. and Hökfelt T. (1988) Chemical messengers and their coexistence in individual neurons. News Pharmacol. Sci. 3, 1-5.
29. Moroni F., Bianchi C., Tanganelli S., Moneti G., and Beani L. (1981) The release of γ-aminobutyric acid, glutamate, and acetylcholine from striatal slices: a mass fragmentographic study. J. Neurochem. 36, 1691-1699.
30. Noble F. and Roques B. P. (1999) CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog. Neurobiol. 58, 349-379.
31. 3H]gamma-aminobutyric acid release in slices from various brain areas. Eur. J. Pharmacol. 250, 423-430.
32. Raiteri M., Bonanno G., Paudice P., Cavazzani P., and Schmid G. (1996) Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors. J. Pharmacol. Exp. Ther. 278, 747-751.
33. Reggiani A., Gerrard P. A., Maraia G., Melotto S., Ratti E., Gaviraghi G., and Trist D. G. (1995) Anxiolytic activity of GV 150013, a new potent and selective cholecystokinin-B (CCK-B) antagonist. Br. J. Pharmacol. 114, 92P.
34. Rehfeld J. F. (1985) Neuronal cholecystokinin: one or multiple transmitters? J. Neurochem. 44, 1-10.
35. Rex A., Barth T., Voigt J. P., Domeney A. M., and Fink H. (1994) Effects of cholecystokinin tetrapeptide and sulphated cholecystokinin octapeptide in rat models of anxiety. Neurosci. Lett. 172, 139-142.
36. Schacht U. and Bäcker G. (1979) In vitro studies on GABA release. Br. J. Clin. Pharmacol. 1, 25S-31S.
37. Sheehan M. J. and de Belleroche J. (1983) Facilitation of GABA release by cholecystokinin and caerulein in rat cerebral cortex. Neuropeptides 3, 429-434.
38. Singh L., Field M. J., Hughes J., Menzies R., Oles R. J., Vass C. A., and Woodruff G. N. (1991) The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br. J. Pharmacol. 104, 239-245.
39. Tallman J., Thomas J., and Gallager D. (1978) GABAergic modulation of benzodiazepine binding site sensitivity. Nature 274, 383-385.
40. Trist D. G. and Reggiani A. (1996) Cholecystokinin-B (CCK-B) receptor antagonist and anxiety. Pharmacol. Rev. Commun. 8, 1-8.
41. Vanderhaeghen J. J., Signeau J. C., and Gepts W. (1975) New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257, 604-605.
42. Woodruff G. N., Hill D. R., Boden P., Pinnock R., Singh L., and Hughes J. (1991) Functional role of brain CCK receptors. Neuropeptides 19 (Suppl.), 45-56.
43. Yaksh T. L., Furui T., Kanawati I. S., and Go V. L. (1987) Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems. Brain Res. 406, 207-214.
44. You Z. B., Godukhin O., Goiny M., Nylander I., Ungerstedt U., Terenius L., Hökfelt T., and Herrera-Marschitz M. (1997) Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. Naunyn Schmiedebergs Arch. Pharmacol. 355, 576-581.
45. Yunger L. M., Fowler P. J., Zarevics P., and Setler P. E. (1984) Novel inhibitors of gamma-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. J. Pharmacol. Exp. Ther. 228, 109-115.